Biocardia Inc (BCDA) Stock Price, Chart & News

Earn 10$ Cash for every Pro+ Friend you Refer!

BCDA

2.16

USD-0.06-2.92%

Overview

Profile

Statistics

Earnings

Financials

Holders

Trends

Insider Trades

Filings

News

Chart

Latest News

@eWhispers

1 year

#earnings after the close https://t.co/lObOE0dgsr $RH $CNXC $PL $CXM $FUL $XOS $SMTC $DFLI $BEEM $DYAI $VRNT $FC $REED $VQS $DERM $AXDX $OCX $OPGN $VIEW $BCDA $IVA $BCEL https://t.co/gfrPqaHSBR

Analysts Recommendations

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Day Range

2.14USD

2.31USD

52 Week Range

0.30USD

5.69USD

Market Cap

9.75MUSD

About

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

General Information

Type

Common Stock

Exchange

NASDAQ

Currency Code

USD

Currency Name

US Dollar

Country Name

USA

Country ISO

ISIN

US09060U5074

CUSIP

14161L109

Sector

Healthcare

Industry

Biotechnology

Fiscal Year End

December

IPO date

Updated At

Highlights

PE Ratio

PEG Ratio

Book Value

-1.02

Dividend Share

Dividend Yield

Earnings Share

-4.03

Wall Street Target Price

EPS Estimate Current Year

-3.52

EPS Estimate Next Year

-1.22

EPS Estimate Current Quarter

EPS Estimate Next Quarter

Most Recent Quarter

Profitability

Revenue TTM

428,000

Gross Profit TTM

-4,641,000

EBITDA

-8,529,000

Profit Margin

0.00%

Return On Assets TTM

-115.93%

Return On Equity TTM

-703.62%

Revenue Per Share TTM

0.264

Qtly Revenue Growth YOY

-93.00%

Diluted Eps TTM

-4.03

Qtly Earnings Growth YOY

0.00%

Valuation

Trailing PE

0.00

Forward PE

Price Sales TTM

24.0996

Price Book MRQ

3.7467

Enterprise Value Revenue

Enterprise Value EBITDA

-3

Peers analysis

CMXHFCSL Limited
169.54
3.19%
CSLLYCSL Ltd
86.83
0.51%
ARGNFargenx SE
655.00
0.00%
UCBJFUCB SA
194.85
0.00%
ALNYAlnylam Pharmaceuticals Inc
240.51
-7.01%

REGNRegeneron Pharmaceuticals Inc
694.00
-3.22%
BNTXBioNTech SE
112.43
-1.09%
ARGXargenx NV ADR
665.60
-0.72%
VRTXVertex Pharmaceuticals Inc
412.28
-0.27%
UCBJYUCB SA ADR
97.63
-0.27%

What are you waiting for?Start making profit today

Tools

Plans

Markets

Resources

Compare

Profit mobile app

Discover the world of finance in your pocket

2025